Astrana Health Inc. is a public company focused on the advancement of healthcare solutions aimed at improving patient outcomes and enhancing the overall quality of care
The company develops innovative products and services that leverage technology to address various health challenges, including chronic diseases and mental health conditions. By integrating research and development with clinical expertise, Astrana Health strives to create effective treatment options and support systems that empower both patients and healthcare providers. Their commitment to innovation and patient-centered care positions them as a formidable player in the evolving healthcare landscape.
What a brutal six months it’s been for Astrana Health. The stock has dropped 47.7% and now trades at $29.91, rattling many shareholders. This may have investors wondering how to approach the situation.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Shares of healthcare services company Astrana Health
fell 31.9% in the afternoon session after the company reported weak fourth quarter results, its full-year EBITDA guidance missed significantly and its EPS fell short of Wall Street's estimates. On the other hand, Astrana Health blew past analysts' revenue expectations, driven by a nearly twofold increase in Care Partners sales. Looking ahead, the company expects 2025 revenue growth of at least 28%, a significant deceleration from the prior year. Overall, this was a weaker quarter.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Healthcare services company Astrana Health announced better-than-expected revenue in Q4 CY2024, with sales up 88.4% year on year to $665.2 million. The company expects the full year’s revenue to be around $2.6 billion, close to analysts’ estimates. Its GAAP loss of $0.15 per share was significantly below analysts’ consensus estimates.
